Skip to main content
. 2022 Feb 11;6(5):1032–1044. doi: 10.1002/hep4.1877

TABLE 1.

Baseline Demographic, Metabolic, Laboratory, Histologic, and Genetic Features of Entire Cohort Stratified For Low Risk of Fibrosis (FIB‐4 < 1.3) and Intermediate/High Risk of Fibrosis (FIB‐4 ≥ 1.3)

FIB‐4 < 1.3 (n = 3 17) FIB‐4 ≥ 1.3 (n = 229) P Value
Mean age, years 43 ± 12.3 61.6 ± 9.1 <0.001
Age ≥ 50 years 34.1% 90.8% <0.001
Male sex 70% 56.8% 0.001
Mean BMI 29.74 ± 5 31.8 ± 5.7 0.34
Obesity (BMI ≥ 30 kg/m2) 40.1% 61.6% <0.001
Blood glucose, mg/dL 98.9 ± 33.3 113.8 ± 35.4 0.01
Total cholesterol, mg/dL 200 ± 43.4 180.2 ± 48 0.32
HDL, mg/dL 49.2 ± 13.9 48.8 ± 16.9 0.03
HDL <40 mg/dL in males 33.1% 38.4% 0.20
<50 mg/dL in females
Triglycerides, mg/dL 146 ± 97.5 131 ± 63.1 0.004
Triglycerides ≥ 150 mg/dL 36.9% 28.4% 0.03
AST, IU/L 39.5 ± 20.2 49.1 ± 31.6 0.001
ALT, IU/L 78.1 ± 53.1 57.9 ± 41 0.02
Albumin, g/L 4.6 ± 0.3 4.2 ± 0.4 <0.001
Albumin ≥ 4 g/L 3.1% 25.3% <0.001
PLTs, 103/mm3 262.6 ± 77.7 160.3 ± 67.2 <0.001
PLTs ≥ 110 × 103/mm3 0 21.4% <0.001
Type 2 diabetes 22.7% 57.6% <0.001
Arterial hypertension 29.3% 58.5% <0.001
Statin users 17.9% 24.0% 0.11
Metformin users 30.0% 27.9% 0.68
PNPLA3 rs738409 CC/CG/GG 35/45.7/19.2% 25.8/46.3/27.9% 0.01
TM6SF2 rs58542926 CC/CT/TT 72.5/24.3/2.2% 72.9/24.4/2.6% 0.95
HSD17B13 rs72613567 T/TA/TATA 65.6/30.6/3.8% 74.2/22.7/3.1% 0.09
Time of follow‐up, months 79.4 ± 42.9 66.1 ± 37.3 0.03

Data are given as mean ± SD or as percentage (%) of cases.